Yang H, Chen Z J, Kageshita T, Yamada M, Ferrone S
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.
Eur J Immunol. 1993 Jul;23(7):1671-7. doi: 10.1002/eji.1830230741.
The mouse anti-idiotypic (anti-id) monoclonal antibody (mAb) MK2-23 bears the internal image of the determinant defined by the syngeneic immunizing anti-human high molecular weight melanoma-associated antigen (HMW-MAA) mAb 763.74, since it induces anti-HMW-MAA antibodies in syngeneic and xenogeneic hosts. To dissect the humoral immune response induced by mAb MK2-23 at the clonal level, 1351 hybridomas were generated from a BALB/c mouse immunized with mAb MK2-23. Serological and immunochemical assays showed that the anti-anti-idiotypic (anti-anti-id) mAb GH827, GH1002 and GH1081 react only with the immunizing anti-id mAb MK2-23 and that the anti-anti-id mAb GH149, GH368, GH464, GH518, GH586, GH704, GH786 and GH1151 react with both mAb MK2-23 and HMW-MAA. The eight HMW-MAA binding anti-anti-id mAb resembled mAb 763.74 in their reactivity patterns with a panel of cell lines, although the extent of reactivity was lower. Staining of surgically removed melanoma lesions detected subtle differences in the reactivity patterns of the eight HMW-MAA binding anti-anti-id mAb. This finding in conjunction with the differential ability of the eight anti-anti-id mAb to inhibit the binding of anti-HMW-MAA mAb 763.74 to melanoma cells and to mAb MK2-23 and with the different avidity of the binding to mAb MK2-23 suggest diversity in the fine specificity of the eight HMW-MAA binding anti-anti-id mAb. Like mAb 763.74, the eight HMW-MAA binding anti-anti-id mAb express the idiotopes recognized by the anti-id mAb MK2-23 and MK2-120. In contrast, the three anti-anti-id mAb GH827, GH1002 and GH1081, which do not bind HMW-MAA binding anti-anti-id mAb to the antibodies elicited by the membrane-bound HMW-MAA corroborates the validity of the use of anti-id mAb MK2-23 as an immunogen to implement active specific immunotherapy in patients with malignant melanoma.
小鼠抗独特型(抗-Id)单克隆抗体(mAb)MK2-23具有同基因免疫抗人高分子量黑色素瘤相关抗原(HMW-MAA)mAb 763.74所定义的决定簇的内影像,因为它能在同基因和异种宿主中诱导产生抗HMW-MAA抗体。为了在克隆水平剖析mAb MK2-23诱导的体液免疫反应,用mAb MK2-23免疫一只BALB/c小鼠,产生了1351个杂交瘤。血清学和免疫化学分析表明,抗抗独特型(抗-抗-Id)mAb GH827、GH1002和GH1081仅与免疫抗-Id mAb MK2-23反应,而抗-抗-Id mAb GH149、GH368、GH464、GH518、GH586、GH704、GH786和GH1151则与mAb MK2-23和HMW-MAA都反应。这8种与HMW-MAA结合的抗-抗-Id mAb在与一组细胞系的反应模式上类似于mAb 763.74,尽管反应程度较低。对手术切除的黑色素瘤病变进行染色,发现这8种与HMW-MAA结合的抗-抗-Id mAb的反应模式存在细微差异。这一发现与这8种抗-抗-Id mAb抑制抗HMW-MAA mAb 763.74与黑色素瘤细胞结合以及与mAb MK2-23结合的不同能力,以及与mAb MK2-23结合的不同亲和力相结合,表明这8种与HMW-MAA结合的抗-抗-Id mAb在精细特异性上存在多样性。与mAb 763.74一样,这8种与HMW-MAA结合的抗-抗-Id mAb表达了抗-Id mAb MK2-23和MK2-120所识别的独特型。相比之下,不与HMW-MAA结合的3种抗-抗-Id mAb GH827、GH1002和GH1081,将与膜结合HMW-MAA引发的抗体结合的抗-抗-Id mAb与抗-Id mAb MK2-23作为免疫原用于对恶性黑色素瘤患者实施主动特异性免疫治疗的有效性得到了证实。